GAS5 and neoplasm: Recently, Li et al. (2016) observed that GAS5 expression was significantly down-regulated (∼2.7-fold) in trastuzumab-resistant TR SKBR-3 cells and trastuzumab-resistant breast cancer patients (n = 86) compared to non-tumor tissues, as assessed by real-time PCR [13].